leadf
logo-loader
viewBioPorto

BioPorto begins enrolling in its clinical study to treat children with severe acute kidney injury

BioPorto A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive it has begun enrollment of the first patients in its clinical study of its NGAL Test for moderate to severe acute kidney injury in children.

Eriksen says while the Danish firm is paying attention to the recent coronavirus outbreaks in the southern area of the US, BioPorto reiterates its expectations of completing the trial and filing the FDA submission in the second half of 2020.

Quick facts: BioPorto

Price: 0.4 USD

PINK:THOXF
Market: PINK
Market Cap: $106.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

BioPorto maintains sales momentum of NGAL test, begins patient enrollment...

BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive in its third quarter, NGAL Test revenue was up 17% compared to the same quarter last year, proving that revenue from the test has not been affected by delays caused by the coronavirus pandemic. Eriksen says what's more,...

on 11/19/2020

2 min read